| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Anzejs Dmuhovskis, Maris Taub. Cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report. Frontiers in psychiatry. vol 15. 2024-09-05. PMID:39234624. |
cariprazine and clozapine combination for the treatment of psychosis in a young, female patient with schizophrenia: a case report. |
2024-09-05 |
2024-09-08 |
Not clear |
| Carlos De Las Cuevas, Victoria C de Leon, Hilario Blasco-Fontecilla, Enrique Baca-García, Marina Sagud, Emilio J Sanz, Jose de Leo. Clozapine may consistently protect from suicidal behaviors while other antipsychotics may lack a specific protective effect: a comprehensive VigiBase study interpreted in the context of the prior literature. Expert opinion on drug safety. 2024-09-03. PMID:39223773. |
in the united states clozapine was first approved for treatment-resistant schizophrenia and then for suicidality in schizophrenia psychoses. |
2024-09-03 |
2024-09-05 |
Not clear |
| Chenghao Lu, Xiaoying Jin, Nannan Liu, Yanzhe Li, Yeqing Dong, Xinxu Wang, Shen Li, Jie L. The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort. Brain research. 2024-09-02. PMID:39222872. |
the relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large chinese schizophrenia cohort. |
2024-09-02 |
2024-09-05 |
Not clear |
| Chenghao Lu, Xiaoying Jin, Nannan Liu, Yanzhe Li, Yeqing Dong, Xinxu Wang, Shen Li, Jie L. The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort. Brain research. 2024-09-02. PMID:39222872. |
this study explores the intricate relationship between clozapine use, cardiovascular disease (cvd) risk, and cognitive function in patients with schizophrenia (scz). |
2024-09-02 |
2024-09-05 |
Not clear |
| Helio Elkis, Debora Luciana Melzer-Ribeiro, Isabel Cristina Napolitan. Response to Markota et al. "Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia" SCHRES-D-24-00481. Schizophrenia research. vol 272. 2024-08-30. PMID:39214020. |
"clinical heterogeneity and ect in patients with clozapine resistant schizophrenia" schres-d-24-00481. |
2024-08-30 |
2024-09-04 |
Not clear |
| Aviv Segev, Risha Govind, Ebenezer Oloyede, Hamilton Morrin, Amelia Jewell, Rowena Jones, Laura Mangiaterra, Stefano Bonora, Ehtesham Iqbal, Robert Stewart, Matthew Broadbent, James H MacCab. Developing a validated methodology for identifying clozapine treatment periods in electronic health records. BMC psychiatry. vol 24. issue 1. 2024-08-28. PMID:39192241. |
clozapine is the only recommended antipsychotic medication for individuals diagnosed with treatment-resistant schizophrenia. |
2024-08-28 |
2024-08-30 |
Not clear |
| Yanzhe Li, Minghuan Zhu, Yeqing Dong, Nannan Liu, Xinxu Wang, Bing Yang, Zezhi Li, Shen L. Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients. European archives of psychiatry and clinical neuroscience. 2024-08-28. PMID:39196353. |
patients with treatment-resistant schizophrenia (trs), particularly those resistant to clozapine (ctrs), pose a clinical challenge due to limited response to standard antipsychotic treatments. |
2024-08-28 |
2024-08-30 |
Not clear |
| Matej Markota, Paul E Croarkin, Brandon J Coombes, Melanie T Gentry, Jonathan G Leun. Clinical heterogeneity and ECT in patients with clozapine resistant schizophrenia. Schizophrenia research. vol 272. 2024-08-28. PMID:39197319. |
clinical heterogeneity and ect in patients with clozapine resistant schizophrenia. |
2024-08-28 |
2024-09-01 |
Not clear |
| Yuhei Suzuki, Kenya Watanabe, Keiko Kanno-Nozaki, Sho Horikoshi, Mizue Ichinose, Yoichiro Hirata, Yuri Kobayashi, Satoshi Takeuchi, Kouichi Osonoe, Shuzo Hoshino, Itaru Miur. Factors associated with cognitive dysfunction in treatment-responsive and -resistant schizophrenia: A pilot cross-sectional study. Journal of psychiatric research. vol 178. 2024-08-20. PMID:39163661. |
we aimed to clarify the association between cognitive dysfunction and factors, such as plasma concentrations of clozapine (clz), n-desmethylclozapine (ndmc), and homovanillic acid (hva), due to differences in antipsychotic responses in patients with schizophrenia. |
2024-08-20 |
2024-08-23 |
Not clear |
| Yin Cao, Qingrong Xia, Jun Liang, Jiequan Wang, Feng Shan, Biao Da. Effect of Common Cold on Serum Clozapine Concentrations in Hospitalized Patients with Schizophrenia. Neuropsychiatric disease and treatment. vol 20. 2024-08-19. PMID:39156033. |
effect of common cold on serum clozapine concentrations in hospitalized patients with schizophrenia. |
2024-08-19 |
2024-08-21 |
Not clear |
| Yin Cao, Qingrong Xia, Jun Liang, Jiequan Wang, Feng Shan, Biao Da. Effect of Common Cold on Serum Clozapine Concentrations in Hospitalized Patients with Schizophrenia. Neuropsychiatric disease and treatment. vol 20. 2024-08-19. PMID:39156033. |
the present study aims to investigate the effect of common cold on the serum clozapine concentrations in hospitalized patients with schizophrenia. |
2024-08-19 |
2024-08-21 |
Not clear |
| Steven Parkes, Bethany Mantell, Ebenezer Oloyede, Graham Blackma. Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144802. |
patients' experiences of clozapine for treatment-resistant schizophrenia: a systematic review. |
2024-08-15 |
2024-08-17 |
Not clear |
| Steven Parkes, Bethany Mantell, Ebenezer Oloyede, Graham Blackma. Patients' Experiences of Clozapine for Treatment-Resistant Schizophrenia: A Systematic Review. Schizophrenia bulletin open. vol 3. issue 1. 2024-08-15. PMID:39144802. |
clozapine is the most effective antipsychotic for patients with treatment-resistant schizophrenia (trs), however, it remains widely under-utilized in clinical practice. |
2024-08-15 |
2024-08-17 |
Not clear |
| Suresh Thapaliya, Eromona Whiskey, Mudasir Firdos. Effective and safe use of intramuscular clozapine in a patient presenting with catatonia and thrombocytopenia. BMJ case reports. vol 17. issue 8. 2024-08-14. PMID:39142837. |
clozapine is the most effective medication for the management of treatment-resistant schizophrenia and schizoaffective disorder, and its discontinuation can pose significant challenges in treatment. |
2024-08-14 |
2024-08-17 |
Not clear |
| Lene Bleich, Renate Grohmann, Waldemar Greil, Dominik Dabbert, Andreas Erfurth, Sermin Toto, Johanna Seifer. Clozapine-associated adverse drug reactions in 38,349 psychiatric inpatients: drug surveillance data from the AMSP project between 1993 and 2016. Journal of neural transmission (Vienna, Austria : 1996). 2024-08-13. PMID:39136776. |
clozapine is a second-generation antipsychotic drug that offers superior treatment results in patients with schizophrenia but is also associated with significant risks. |
2024-08-13 |
2024-08-16 |
Not clear |
| Marco Solmi, Giovanni Croatto, Arnav Gupta, Nicholas Fabiano, Stanley Wong, Michele Fornaro, Lynne Kolton Schneider, S Christy Rohani-Montez, Leanne Fairley, Nathalie Smith, István Bitter, Philip Gorwood, Heidi Taipale, Jari Tiihonen, Samuele Cortese, Elena Dragioti, Ebba Du Rietz, Rene Ernst Nielsen, Joseph Firth, Paolo Fusar-Poli, Catharina Hartman, Richard I G Holt, Anne Høye, Ai Koyanagi, Henrik Larsson, Kelli Lehto, Peter Lindgren, Mirko Manchia, Merete Nordentoft, Karolina Skonieczna-Żydecka, Brendon Stubbs, Davy Vancampfort, Michele De Prisco, Laurent Boyer, Eduard Vieta, Christoph U Correl. Effects of antipsychotic treatment on cardio-cerebrovascular related mortality in schizophrenia: A subanalysis of a systematic review and meta-analysis with meta-regression of moderators. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 88. 2024-08-09. PMID:39121717. |
conversely, second generation antipsychotics (sgas) and clozapine were associated with reduced cardio-cerebrovascular-related mortality, in prevalent samples of schizophrenia. |
2024-08-09 |
2024-08-13 |
Not clear |
| Qi He, Peixin Zhu, Xiyan Liu, Chunyue Hu. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophrenia research. vol 271. 2024-08-07. PMID:39111258. |
association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: a systematic review and meta-analysis. |
2024-08-07 |
2024-08-10 |
Not clear |
| Qi He, Peixin Zhu, Xiyan Liu, Chunyue Hu. Association of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine versus patients treated with olanzapine, risperidone, or quetiapine: A systematic review and meta-analysis. Schizophrenia research. vol 271. 2024-08-07. PMID:39111258. |
we aimed to compare the risk of new-onset diabetes mellitus in adults with schizophrenia treated with clozapine and other sgas. |
2024-08-07 |
2024-08-10 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Kohei Kitagawa, Yuji Yada, Masafumi Kodama, Shinichiro Nakajima, Yoshiki Kishi, Norihito Yamada, Hiroyoshi Takeuch. Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: A 1-year retrospective cohort study. Psychopharmacology. 2024-08-06. PMID:39105768. |
impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: a 1-year retrospective cohort study. |
2024-08-06 |
2024-08-08 |
Not clear |
| Masaru Tsukahara, Ryuhei So, Kohei Kitagawa, Yuji Yada, Masafumi Kodama, Shinichiro Nakajima, Yoshiki Kishi, Norihito Yamada, Hiroyoshi Takeuch. Impact of clozapine once-daily versus multiple-daily dosing regimen on relapse in patients with treatment-resistant schizophrenia: A 1-year retrospective cohort study. Psychopharmacology. 2024-08-06. PMID:39105768. |
clozapine, the standard treatment for treatment-resistant schizophrenia (trs), is generally recommended in a multiple-daily dosing regimen. |
2024-08-06 |
2024-08-08 |
Not clear |